Daiichi Sankyo Submits Benicar/Amlodipine Fixed-Dose Combination To FDA
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo submitted an NDA Nov. 27 for a fixed-dose combination of its angiotensin receptor blocker Benicar (olmesartan) and the calcium channel blocker amlodipine (currently marketed by Pfizer as Norvasc). The Japanese drug maker told "The Pink Sheet" DAILY it is seeking a standard review for treatment of hypertension
You may also be interested in...
EMEA Issues Negative Opinion For Novartis’ Anti-Infective Mycograb
Firm also receives positive opinions from EU authorities on hypertension combo Exforge and macular degeneration treatment Lucentis.
Novartis’ Exforge Has Late December User Fee Date
Novartis’ combination anti-hypertensive is already pending in the EU.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).